Rectal cancer recurrent – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Fri, 12 Jun 2026 10:33:10 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Rectal cancer recurrent – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Study Comparing Chemotherapy with Irinotecan, Folinic Acid, and Oxaliplatin for Patients with Locally Recurrent Rectal Cancer https://clinicaltrials.eu/trial/study-comparing-chemotherapy-with-irinotecan-folinic-acid-and-oxaliplatin-for-patients-with-locally-recurrent-rectal-cancer/ Wed, 29 Apr 2026 14:30:14 +0000 https://clinicaltrials.eu/trial/study-comparing-chemotherapy-with-irinotecan-folinic-acid-and-oxaliplatin-for-patients-with-locally-recurrent-rectal-cancer/ This clinical trial is focused on studying treatments for locally recurrent rectal cancer, which is a type of cancer that returns in the rectum after initial treatment. The study is comparing two different approaches to treatment. One group of patients will receive a combination of chemotherapy drugs before undergoing chemoradiotherapy, while the other group will receive chemoradiotherapy alone. The chemotherapy drugs being used in this study include Irinotecan Hydrochloride, Calcium Folinate (also known as Folinic Acid), Teysuno (which contains Tegafur, Gimeracil, and Oteracil), Oxaliplatin, Fluorouracil, and Xeloda (which contains Capecitabine).

The purpose of the study is to compare the effectiveness of these two treatment approaches in achieving clear resection margins, which means removing the cancer completely during surgery. Participants in the study will be randomly assigned to one of the two treatment groups. Those in the chemotherapy group will receive the drugs through intravenous infusion or oral tablets over a period of time before starting chemoradiotherapy. The study will monitor the participants’ progress and response to the treatments, as well as any side effects they may experience.

Throughout the study, participants will undergo regular assessments to track their health and the status of their cancer. These assessments may include imaging tests like MRI to evaluate the cancer’s response to treatment. The study aims to provide valuable information on the best approach to treating locally recurrent rectal cancer, potentially improving outcomes for patients with this condition.

]]>